<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="administration of lopinavir/ritonavir, an anti-human immunodeficiency virus (HIV) drug, and" exact="ceftriaxone" post="were commenced. Figure 2 illustrates the course of use"/>
 <result pre="We initiated mechanical ventilation in the pressure-controlled mode. Sedation with" exact="propofol" post="and fentanyl and administration of dopamine and noradrenaline were"/>
 <result pre="mechanical ventilation in the pressure-controlled mode. Sedation with propofol and" exact="fentanyl" post="and administration of dopamine and noradrenaline were commenced after"/>
 <result pre="pressure-controlled mode. Sedation with propofol and fentanyl and administration of" exact="dopamine" post="and noradrenaline were commenced after intubation. The antibiotic was"/>
 <result pre="day 24 with improvement in his symptoms. The administration of" exact="chloroquine" post="was also resumed on day 24. On day 32,"/>
 <result pre="not be recommended for COVID-19 treatment [11]. Next, we administered" exact="chloroquine" post="twice, on days 6-7 and on days 24â€“40. Since"/>
 <result pre="effect of favipiravir would outweigh that of chloroquine, we used" exact="chloroquine" post="as a substitute until favipiravir became available. It is"/>
 <result pre="a substitute until favipiravir became available. It is unclear whether" exact="chloroquine" post="was effective or not because of the short period"/>
 <result pre="already on a recovery course in the second period. Furthermore," exact="chloroquine" post="was suspected to be a cause of liver dysfunction"/>
 <result pre="virus disease therapeuticsNew England Journal of Medicine2019381242293230310.1056/nejmoa191099331774950 7WangM.CaoR.ZhangL.et al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
</results>
